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Abstract 
Tamoxifen is a commonly used drug to treat estrogen receptor-positive patients with breast cancer. Despite 
the outstanding efficacy of tamoxifen, approximately one-third of patients develop resistance toward it, thereby 
presenting a therapeutic challenge. HOX genes may be involved in the acquisition of tamoxifen resistance. In 
this study, we identified HOXA5, a member of the HOX gene family, as a marker of tamoxifen resistance. Using 
ChIP assay, we found that HOXA5 expression was significantly overexpressed in tamoxifen-resistant MCF7 
(TAMR) breast cancer cells because of reduced H3K27me3 binding. HOXA5 upregulation resulted in 
activation of the PI3K/AKT signaling cascade, which in turn, led to p53 and p21 reduction, ultimately making the 
TAMR cells less apoptotic. Furthermore, elevated HOXA5 expression resulted in breast cancer cells acquiring 
more mesenchymal-like and stem cell traits associated with aggressive breast cancer phenotypes. In conclusion, 
our results delineate a mechanism by which HOXA5 promotes tumorigenesis, cancer progression, and 
tamoxifen resistance in breast cancer cells. 
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Introduction 
Cancer is characterized by uncontrolled cell 
division that commonly turns malignant and 
metastasizes by migrating and invading other healthy 
tissues in the body [1, 2]. Among various types of 
cancer, breast cancer is one of the most prevalent 
cancers worldwide [3-5]. It involves the formation of 
malignant tumors in the breast tissues, usually in the 
ducts of the terminal duct lobular unit [6]. Breast 
cancer can be classified into four different molecular 
subtypes: luminal A (estrogen receptor/progesterone 
receptor-positive [ER/PR+], human epidermal 
growth factor receptor 2-negative [HER2-]), luminal B 
(ER/PR+, HER2+), triple negative (ER/PR-, HER2-), 
and HER2-enriched (ER/PR-, HER2+) [7], of which 
the ER+ subtype is the most prevalent. ER+ cases are 
typically treated with drugs belonging to the class of 
selective ER modulators (SERMs) [8, 9]. Tamoxifen, 
one of the most commonly administered SERMs, 
competes with estradiol, a major estrogen sex 
hormone for ER binding, to function as a partial ER 
antagonist and a transcriptional inhibitor of 
estrogen-responsive genes, thereby inhibiting breast 
cancer growth. The robustness of tamoxifen makes it 
an excellent drug for administration in both pre- and 
post-menopausal females, as well as in male patients 
with breast cancer [10]. However, approximately 
one-third of patients eventually develop resistance to 
tamoxifen, ultimately leading to relapse and 
eventually metastatic breast cancer [11-14]. Although 
there are extensive studies on the mechanisms 
underlying the development of tamoxifen resistance, 
knowledge on molecular markers that can predict 
tamoxifen resistance and thus breast cancer relapse is 
still lacking. Therefore, it is imperative to identify 
novel biomarkers of tamoxifen resistance to overcome 
major obstacles in improving existing therapies for 
the treatment and prevention of breast cancer. 
The homeobox (HOX) genes are a group of 
highly conserved genes organized into four different 
clusters: HOXA, HOXB, HOXC, and HOXD. These 
genes play central roles in encoding transcription 








axis during embryogenesis [15-20]. The collinear 
expression of HOX genes has been extensively studied 
to reveal the mechanism underlying sequential 
patterning of the body axis and secondary axial 
structures of an embryo in space and time [20-22]. 
More recently, dysregulated HOX expression has 
been identified in cancer [23-26]. The altered 
expression of HOX genes has been studied in various 
cancers such as colon, lung, ovarian, prostate, and 
breast cancer [27-32], wherein it may play an 
oncogenic or tumor-suppressive role. Interestingly, 
specific HOX genes may play both oncogenic and 
tumor-suppressive roles in a tumor site-specific 
manner. Abnormal expression of certain HOX genes 
can promote tumorigenesis by evading apoptosis, 
altering signaling pathways, and promoting 
epithelial–mesenchymal transition (EMT). In contrast, 
other HOX genes can induce differentiation of cancer 
cells to prevent tumor growth and proliferation [33, 
34]. Nevertheless, the precise functional mechanism of 
HOX genes in regulating tamoxifen resistance in 
breast cancer is yet to be elucidated. 
Many HOX dysregulations have been explained 
through epigenetic mechanisms [16, 35]. The 
expression of HOX genes is commonly controlled by 
epigenetic regulations such as DNA methylation and 
histone modifications during normal development or 
cancer [16, 35-37]. In particular, histone modifications 
regulated by histone methyltransferases, histone 
demethylases, and histone acetyltransferases can 
result in dynamic conformational changes in the 
chromosome, which results in discrepant HOX 
expression [16, 35-38]. 
In this study, we aimed to investigate the 
molecular mechanisms underlying the role of HOXA5 
in tamoxifen resistance. Using a systematic in vitro 
approach to analyze the function of HOXA5, we 
found that higher levels of HOXA5 in 
tamoxifen-resistant MCF7 (TAMR) breast cancer cells 
activated the PI3K/AKT signaling pathway and 
resulted in reduced p53 and p21 levels and 
significantly reduced proportion of apoptotic cells 
after tamoxifen treatment. Enhanced metastasizing 
capabilities and an enrichment of breast cancer stem 
cells were also associated with HOXA5 
overexpression. Overall, our results revealed the 
mechanism by which HOXA5 acts as an important 
factor in the acquisition of tamoxifen resistance and 
enhancement of breast cancer aggressiveness and 
implied that modulation of HOXA5 expression and its 
related downstream pathways can demonstrate 
noteworthy benefits for patients experiencing drug 
resistance and disease recurrence. 
Materials and methods 
Cell lines and culture 
MCF7 and MCF7-TAMR cells were cultured in 
Dulbecco’s modified Eagle’s medium (WelGENE Inc., 
Daegu, Korea). The medium was supplemented with 
heat-inactivated 10% FBS (WelGENE Inc.) and 1% 
penicillin-streptomycin (WelGENE Inc.). In case of the 
MCF7-TAMR cells, the medium additionally 
contained 1 μM 4-hydroxytamoxifen (Sigma, MO, 
USA). All cells were grown at 37 °C in a 5% CO2 
incubator. TAMR cells were generated as in vitro 
models of acquired tamoxifen resistance by exposing 
the parent cell lines MCF7 for a long-term with 1 μM 
4-hydroxytamoxifen (Sigma) treatment. For 
overexpression studies, MCF7 cells were transfected 
with the HOXA5 plasmid (pCMV6-AC-GFP vector 
backbone; OriGene Technologies, Inc., Rockville, MD, 
USA) for 24 h using the Attractene transfection 
reagent (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. Knockdown studies were 
performed by transfecting TAMR cells for 24–48 h 
with 40 nM siHOXA5 using G-fectin (Genolution, 
Seoul, Korea) following the manufacturer’s protocol. 
A pool of 5 individual siRNAs targeting exons 1 and 2 
of HOXA5 were used for the knockdown. 
Reverse transcription (RT)-qPCR 
 Total RNA was extracted from cells using TRIzol 
reagent (Invitrogen, CA, USA), and cDNA was 
synthesized with 1 μg of total RNA using 
ImProm-IITM Reverse Transcriptase (Promega, WI, 
USA). Reverse transcription was performed under the 
following conditions: initial denaturation for 5 min at 
94 °C, followed by 27-35 cycles of 94 °C for 40 s 
(depending on target genes), 58 °C for 20 s, and 72 °C 
for 30 s. For quantitative PCR, the StepOnePlusTM 
Real-Time PCR System (Applied Biosystems, CA, 
USA) and Power SYBR Green PR Master Mix 
(Applied Biosystems) were used. All qPCR reactions 
were performed in at least three independent 
biological replicates, and β-Actin and GAPDH were 
used as internal controls. The RT-PCR primers are 
listed in Table 1. 
Western blotting 
MCF7 and TAMR cells were treated under the 
appropriate conditions and then lysed with NP-40 
(Biosesang, Sungnam, Korea), after which their 
protein concentrations were determined using the 
Pierce BCA Protein Assay Kit (Thermo Scientific, MA, 
USA). Each protein sample was loaded onto 8-10% 
SDS polyacrylamide gel, and then electro transferred 
to a PVDF transfer membrane (BioRad, CA, USA). 
Immunoreactive bands were detected using target 




primary antibodies and corresponding 
HRP-conjugated secondary antibodies. Bands were 
visualized using the SuperSignal West Pico 
Chemiluminescent Substrate Kit (Thermo Scientific). 
Anti-HOXA5 (ab82645; Abcam), anti-EZH2 (#5246S; 
Cell Signaling, MA, USA), anti-SUZ12 (#3737; Cell 
Signaling), anti-EED (ab96801; Abcam, Cambridge, 
UK), UTX (ab36938; Abcam), anti-JMJD3 (ab169197; 
Abcam), anti-AKT (#2967; Cell Signaling), 
anti-phospho-AKT (Thr308, #9275; Cell Signaling), 
anti-phospho-AKT (Ser473, #4508; Cell Signaling), 
anti-p53 (sc-126; Santa Cruz Biotechnology, CA, 
USA), anti-p21 Waf1/Cip1 (#2947; Cell Signaling), 
anti-Caspase-7 (#12827; Cell Signaling), anti-cleaved- 
Caspase-7 (#8438; Cell Signaling), anti-Caspase-9 
(#9508; Cell Signaling), anti-cleaved-Caspase-9 
(#52873; Cell Signaling), anti-PARP (#9542; Cell 
Signaling), anti-cleaved-PARP (#5625; Cell Signaling), 
anti-E-cadherin (ab40772; Abcam), anti-N-cadherin 
(ab18203; Abcam), anti-ZEB1(ab181451; Abcam), and 
anti-β-Actin (ab6276; Abcam) antibodies were used to 
detect each of the respective proteins. 
 
Table 1. Primer sequences used for RT-PCR 
Genes Sequence (5′ → 3′) 
HOXA5 F- ACC CAC ATC AGC AGC AGA GA 
R- GGC CGC CTA TGT TGT CAT 
SOX2 F- ACA TGA ACG GCT GGA GCA 
R- GCT GCG AGT AGG ACA TGC 
OCT4 F- CTG ATC TGC TGC AGT GTG G 
R- CCT TCC CAC CTG CAC AGA T 
NANOG F- CCT TCC TCC ATG GAT CTG CT 
R- TGA GGT TCA GGA TGT TGG AGA G 
β-Actin F- CAT GTT TGA GAC CTT CAA CAC CCC 
R- GCC ATC TCC TGC TCG AAG TCT AG 
 
Cell proliferation assay 
Relative cell proliferation was measured using 
the Cell Counting Kit-8 (Dojindo Molecular 
Technologies Inc., Kumamoto, Japan) following the 
manufacturer’s protocol. Briefly, 7.5 × 103 cells/well 
were plated and grown on 96-well plates, stained with 
10 μL of WST-8, and incubated for 3 h at 37 °C in a 5% 
CO2 incubator for three consecutive days. The plate 
was then measured for absorbance at 450 nm using a 
Softmax Pro microplate reader (Molecular Devices, 
CA, USA). 
Apoptosis analysis 
The EzWay Annexin V-FITC Apoptosis 
Detection Kit (Komabiotech, Seoul, Korea) was used 
to detect apoptosis. Breast cancer cells (3 × 105 cells 
per cell line) were harvested, centrifuged, and washed 
twice with cold Phosphate Buffered Saline (PBS). The 
washed cells were resuspended in 500 μL of cold 
binding buffer. Subsequently, 1.25 μL (200 μg/mL) of 
the Annexin V-FITC reagent was added and 
incubated at room temperature in the dark for 15 min. 
Cells were washed with 500 μL of cold binding buffer, 
then 10 μL of PI (30 μg/mL) was added, and finally 
analyzed by flow cytometry. 
Chromatin immunoprecipitation (ChIP) 
analysis 
For ChIP analysis, cells were fixed with 1% 
formaldehyde for 15 min at room temperature, and 
then quenched with 2.5 M glycine. Subsequently, the 
cells were lysed on ice for 10 min in SDS buffer 
containing protease inhibitors, and then sonicated 
with Sonics Vibra CellTM (Sonics & Materials Inc., CT, 
USA; 7 min: 10 s pulse, 10 s interval) on ice. The 
fragmented chromatin samples were centrifuged at 
8000 ×g at 4 °C for 5 min and the supernatant was 
collected. The samples were pre-cleared, and then 
incubated overnight at 4 °C with the appropriate 
antibodies and protein-coated A/G agarose beads 
(Santa Cruz) with gentle shaking. The 
immunoprecipitated eluates were reverse 
cross-linked and recovered through DNA purification 
for PCR. Anti-H3K4me3 (ab1012; Abcam), 
anti-H3K9ac (ab12179; Abcam), anti-H3K27me3 
(ab6002; Abcam), anti-EZH2 (#5246S; Cell Signaling), 
anti-SUZ12 (#3737; Cell Signaling), anti-EED 
(ab96801; Abcam), anti-UTX (ab36938; Abcam), 
anti-JMJD3 (ab169197; Abcam), and non-immune 
mouse IgG (sc2025; Santa Cruz) antibodies were used. 
ChIP-PCR primers are listed in Table 2. 
 
Table 2. Primer sequences used for ChIP-PCR assay 
Amplicon sites Sequence (5′ → 3′) 
HOXA5 promoter #1 F- GCT CTC CGG AGC CAA AGT G 
R- TCA TAG TTC CGT GAG CGA GC 
HOXA5 promoter #2 F- GTG CTT GAT TTG TGG CTC GC 
R- GTG ATT CGA AGT CGT ACC CCA 
Gene desert F- GAG AAG GCA CAC AGC TAG GG 
R- CCA AGC TGT ACA GGA GAG GC 
 
Invasion and migration analyses 
For the invasion assay, cells were harvested and 
resuspended in serum-free media, and 100 μL of cell 
suspension (5 × 104 cells) were seeded into inserts that 
were pre-coated with Matrigel (BD, CA, USA) (150 
mg/mL) mixed with coating buffer. Standard media 
with 10% FBS was added to the bottom of the wells. 
After 72 h, the cells on the upper surface of the inserts 
were removed with cotton swabs, and the cells that 
invaded the bottom of the inserts were fixed with 
methanol and stained with DAPI. For the migration 
assay, the same protocol was used in the absence of 
Matrigel. Cells were observed and imaged by 
fluorescent microscopy, and cells were counted using 
Image J software. 




Spheroid formation assay 
Spheroid cultures were grown as described, with 
minor changes [39]. Briefly, 1 × 104 cells/mL were 
counted and resuspended carefully using a 25G 
syringe needle to obtain a single-cell suspension. The 
cells were pelleted, washed with cold PBS, and 
syringe-filtered again to ensure that it remains as a 
single-cell suspension. Cells were then plated onto 
Ultra-Low attachment 6-well plates (Corning, NY, 
USA) with 2 mL DMEM/F12 media (WelGENE Inc.) 
supplemented with 1% PSA, 2% B27, 10 ng/mL FGFb, 
20 ng/mL EGF, 5 μg/mL insulin, and 4 μg/mL 
heparin. Cells were maintained at 37 °C in a 5% CO2 
incubator. The number of spheroids with a diameter 
greater than 50 μm was regularly counted, and when 
there were approximately 100 spheroids of this 
diameter, they were collected by gentle 
centrifugation, dissociated, and then passaged for the 
assessment of self-renewal. 
In silico analysis 
The web-accessible database cBioPortal (http:// 
www.cbioportal.org) was used to assess HOXA5 
abnormalities in breast cancer tissues. The Gene 
Expression across Normal Tumor Tissue (GENT) 
publicly available database (http://medical-genome. 
kribb.re.kr/GENT) was used to evaluate HOXA5 gene 
expression patterns in breast cancer tissues. The 
Kaplan-Meier plotter (http://www.kmplot.com) was 
used for survival analysis. This database allows for 
the assessment of 54,675 genes on overall survival 
(OS) and distant metastasis-free survival (DMFS). To 
investigate the prognostic values of the HOXA5 gene, 
patient samples were classified into low- and 
high-expression groups, using the median as the auto 
select best cutoff. 
Statistical analysis 
All data are expressed as mean ± SD. Statistical 
differences were determined using Student’s t-test or 
one-way ANOVA for pairwise comparisons. A 
p-value of < 0.05 was considered as statistically 
significant. 
Results 
Elevated expression of HOXA5 is associated 
with tamoxifen resistance in breast cancer 
To identify the regulatory molecules involved in 
acquired tamoxifen resistance, we compared the 
expression levels of the complete set of HOX genes in 
between MCF7 and TAMR cells via RT-qPCR. 
Amongst the genes showing differential expression 
levels between the two cell strains, HOXA5 was one of 
the genes which showed a dramatic increase in the 
expression levels in the tamoxifen-resistant breast 
cancer cells (Fig. 1A). Correspondingly, the protein 
levels of HOXA5 also showed a consistent 
upregulation in TAMR cells (Fig. 1B). More 
importantly, survival curves from ER+ breast cancer 
patients without tamoxifen treatment were 
independent of HOXA5 expression as compared to 
survival curves of patients who received tamoxifen 
treatment, which demonstrated that a higher 
expression of HOXA5 resulted in a poorer overall 
survival (Fig. 1C). To determine whether tamoxifen 
resistance acquired by the cells is a direct consequence 
of HOXA5 abundance, HOXA5 was knocked down in 
TAMR cells by multiple small interfering RNAs 
(siRNAs) (Fig. 1D). The functional significance of 
HOXA5 knockdown was confirmed by the CCK-8 cell 
viability assay, which showed that the loss of HOXA5 
expression was sufficient to re-sensitize TAMR cells to 
a high-dose of tamoxifen treatment (Fig. 1E). 
Epigenetic regulation of HOXA5 occurs at its 
putative promoter region 
To investigate the reason behind HOXA5 
upregulation in TAMR cells, epigenetic modifications 
present at the HOXA5 putative promoter region were 
examined via chromatin immunoprecipitation (ChIP) 
coupled with quantitative PCR (ChIP-PCR) assay 
(Fig. 2A). In particular, histone modifications and 
their binding affinities to the putative HOXA5 
promoter region were studied. Active histone marks 
such as histone H3 lysine 4 trimethylation (H3K4me3) 
and histone H3 lysine 9 acetylation (H3K9ac) were 
enriched at similar levels between MCF7 and TAMR 
cells. Interestingly, histone H3 lysine 27 
trimethylation (H3K27me3), a well-known repressive 
marker, could not be found in TAMR cells (Fig. 2B). 
We therefore analyzed factors involved in the 
binding dynamics of H3K27me3 in cells. Levels of the 
PRC2 complex components (EZH2, SUZ12, and EED) 
and the histone demethylases (JMJD3 and UTX), 
along with their protein levels were examined in 
MCF7 and TAMR cells. While the protein levels of 
EZH2, SUZ12, and JMJD3 were comparable between 
the two cell lines, the protein level of EED—the core 
component of the PRC2 complex, was downregulated 
in TAMR cells, whereas the level of UTX—a major 
histone demethylase, was upregulated in TAMR cells 
(Fig. 2C). To further test whether these histone 
modifiers are involved in the epigenetic regulation of 
HOXA5 expression, their enrichment at the HOXA5 
promoter region was confirmed by ChIP-PCR (Fig. 
2D). At the first amplicon site, the binding of JMJD3 
and UTX was dramatically higher in TAMR cells 
whereas, the binding of EZH2 was much higher at the 
second amplicon site in MCF7 cells (Fig. 2D). 





Figure 1. Elevated expression of HOXA5 is associated with tamoxifen resistance in MCF7 breast cancer cells. (A) Reverse transcription-quantitative PCR 
(RT-qPCR) analysis of HOXA5 expression in MCF7 and tamoxifen-resistant breast cancer (TAMR) cells. GAPDH was used to normalize changes in HOXA5 expression levels 
between the two cell lines. (B) Western blotting of HOXA5 in MCF7 and TAMR cells. (C) Kaplan-Meier analysis of overall survival (OS) in estrogen receptor-positive (Luminal 
A and Luminal B) breast cancer patients with and without tamoxifen treatment. (D) RT-PCR analysis of HOXA5 in TAMR cells transiently transfected with pooled siHOXA5 for 
48 hrs. (E) Cell viability curve of cells treated with siHOXA5 in the absence (left panel) and presence of 12 μM tamoxifen (right panel) at days 1, 2, and 3. β-Actin was used as an 
internal control for RT-PCR and western blotting. All experiments were performed in triplicate. ** p < 0.01, *** p < 0.001 compared with siCON by Student’s t-test. 
 
Figure 2. Epigenetic regulation of HOXA5 occurs at its putative promoter region. (A) Schematic depiction of the HOXA5 locus on human chromosome 7. Boxes 
represent exons, lines represent introns, and arrows show the direction of transcription. The gray bars represent the amplicon sites used in chromatin immunoprecipitation-PCR 
(ChIP-PCR). (B) ChIP-PCR analysis of the histone modifications H3K4me3, H3K27me3, and H3K9ac in MCF7 and TAMR cells. (C) Western blotting images showing protein 
levels of the epigenetic modifiers in MCF7 and TAMR cells. β-Actin was used as an internal control. (D) ChIP-PCR analysis of EZH2, SUZ12, EED, JMJD3, and UTX in MCF7 and 
TAMR cells. All experiments were performed in triplicate. *** p < 0.001 compared with MCF7 by Student’s t-test. 




To validate whether the transcriptional 
activation of HOXA5 is directly regulated by the 
binding of JMJD3 and UTX at its promoter, we 
examined the effect of GSK-J4, a JMJD3/UTX 
inhibitor, on HOXA5 expression in MCF7 and TAMR 
cells. Upon GSK-J4 treatment, the expression level of 
HOXA5 was unchanged in MCF7 cells compared to 
DMSO-treated control, since JMJD3 is not bound at 
the HOXA5 promoter in MCF7 cells. On the other 
hand, a significant reduction in HOXA5 expression 
was observed in TAMR cells when JMJD3 and UTX 
histone demethylase binding was inhibited using 
GSK-J4. The expressions of NANOG and OCT4 were 
confirmed as positive and negative controls as 
NANOG showed reduced expression, but OCT4 
remained unchanged with GSK-J4 treatment in a 
previous study [40] (Fig. S1). Altogether, these results 
suggest that the transcription of HOXA5 receives 
epigenetic regulation from multiple factors, and is 
directly regulated by the binding of JMJD3 and UTX 
at its promoter region, thereby explaining its 
differential expression observed between MCF7 and 
TAMR cells. 
HOXA5 downregulates p53/p21 expression via 
activation of the PI3K/AKT signaling pathway 
in TAMR cells 
To elucidate the mechanism of HOXA5 in 
tamoxifen resistance, we sought to identify the 
signaling pathways involving HOXA5. We utilized 
the cBioPortal Pathway Mapper to list altered 
signaling pathways associated with altered levels of 
HOXA5 in breast cancer. Among the listed pathways, 
the PI3K/AKT and TP53 pathways were ranked 
top-most (Fig. S2A and S2B). Other signaling 
pathways such as WNT, NOTCH, MYC, and TGFβ 
showed less correlation with HOXA5 alteration 
frequencies (data not shown). Consequently, we 
checked the protein levels of AKT and 
phosphorylated AKT (pAKT) in MCF7 and TAMR 
cells by western blotting. TAMR cells showed 
enhanced basal levels of both pAKTT308 and pAKTS473 
when compared to MCF7 cells (Fig. 3A). Based on the 
above observations, we hypothesized that HOXA5 
plays a key role in activating the AKT signaling 
cascade. To test this hypothesis, HOXA5 was 
overexpressed in MCF7 cells and silenced in TAMR 
cells. Remarkably, HOXA5 overexpression led to 
increased steady-state levels of AKT activity in MCF7 
cells, which had initially showed basal AKT activity in 
the naïve state. Further, activation of the AKT 
signaling cascade in HOXA5-overexpressing MCF7 
cells resulted in reduced protein levels of p53 and p21, 
the downstream effectors of the AKT pathway (Fig. 
3B). Moreover, the inhibition of HOXA5 in TAMR 
cells was sufficient to override the hyperactive AKT 
signaling, especially at the T308 locus. Furthermore, 
de-activation of the AKT signaling pathway restored 
the expression of p53 and p21 (Fig. 3C). 
To additionally re-confirm that the AKT 
signaling pathway is activated in response to the 
elevated levels of HOXA5 and this activation is key to 
the reduced levels of p53/p21, HOXA5- 
overexpressing MCF7 cells were treated with a highly 
selective PI3K inhibitor – LY294002, which has 
already been shown to block PI3K-dependent AKT 
phosphorylation. Upon treatment with the inhibitor, 
AKT activity induced by HOXA5 overexpression was 
successfully inhibited, resulting in the p53 and p21 
expression levels to be rescued (Fig. 3D). Collectively, 
these data support our hypothesis of the functional 
role of HOXA5 in tamoxifen resistance by regulation 
of the PI3K/AKT pathway. Our data also bolsters the 
point that AKT signaling is an important regulator of 
tumor survival in the presence of tamoxifen in breast 
cancer. 
Since p53 and p21 levels were affected by 
HOXA5 expression, we analyzed the role of HOXA5 
in apoptosis. Flow cytometry analyses were used to 
compare the levels of apoptosis between parent MCF7 
and TAMR cells in the absence and presence of 
high-dose tamoxifen treatment. Approximately 50% 
of MCF7 cells underwent apoptosis when exposed to 
high-dose tamoxifen as compared to TAMR cells 
which showed insignificant changes. Further analyses 
revealed that knockdown of HOXA5 in TAMR cells 
also dramatically increased the apoptotic population 
upon tamoxifen treatment compared to that of control 
cells (Fig. 3E). To determine whether the increase in 
the apoptotic activity of the cells is a direct 
consequence of the elevated HOXA5 levels, the 
expressions of pro-apoptotic proteins were explored. 
Elevated levels of caspases, PARP, and their cleaved 
products are considered hallmarks of apoptosis. 
Cleavage activates caspases which then act by 
cleaving a variety of substrates, including PARP and 
ultimately leading to cell death. Hence, protein levels 
of caspase 9, caspase 7, PARP, and their respective 
cleaved forms were investigated. Caspase 3 was 
excluded because it is not expressed in MCF7 cells. 
The basal levels of the inactive full-length caspases 
and PARP were found to be similar between MCF7 
and TAMR cells; however, levels of cleaved caspases 
and PARP were much higher in MCF7 cells compared 
to TAMR cells. This pattern in the expression levels 
stayed consistent even under untreated conditions 
(Fig. 3F). The differential expression between the 
full-length and the cleaved forms became even more 
apparent upon high-dose tamoxifen treatment which 
showed that the levels of cleaved caspases and PARP 




were upregulated in tamoxifen-treated MCF7 cells, 
explaining their sensitivity to tamoxifen, hence 
increasing the apoptotic cell population (Fig. 3G). In 
addition, when HOXA5 was depleted from TAMR 
cells, the molecular levels of cleaved caspases and 
PARP were increased to similar levels seen in the 
MCF7 cells, indicative of impaired DNA repair 
function (Fig. 3H). Combined, these results 
demonstrate that elevated HOXA5 expression 
activates the AKT signaling pathway, which 
consequently reduces p53 and p21 levels, ultimately 
leading to a less apoptotic-prone and tamoxifen- 
resistant phenotype of the cell. 
 
 
Figure 3. HOXA5 downregulates p53/p21 expression via activation of the PI3K/AKT signaling pathway in TAMR cells. (A) Western blotting for basal PI3K/AKT 
activity between parent MCF7 and TAMR cells. (B) Western blotting for PI3K/AKT pathway activation and the downstream p53 and p21 expression in MCF7 cells transfected 
with either the empty vector or HOXA5-overexpressing plasmids. (C) Western blotting for PI3K/AKT activation and downstream p53 and p21 expression in TAMR cells 
transfected with control or HOXA5 siRNAs. (D) Western blotting of PI3K/AKT activity and p53/p21 levels in HOXA5-overexpressing MCF7 cells after treatment with DMSO 
and LY294002 – a highly selective PI3K inhibitor for 24 hrs. (E) Representative scatter plots and quantification graphs showing the distribution of Annexin V and Propidium iodide 
(PI) staining from flow cytometry analysis. Parent cell lines and TAMR cells transfected with control or HOXA5 siRNAs were used for this analysis. Cells are classified as “viable” 
(Q3; bottom left), “early apoptotic” (Q4; bottom right), “late apoptotic” (Q2; top right), or “necrotic” (Q1; top left). (F) Western blotting for basal protein levels of full-length 
and cleaved caspases and PARP in parent MCF7 and TAMR cells. (G) Western blotting for the cleaved forms caspases and PARP after tamoxifen treatment in parent MCF7 and 
TAMR cells. (H) Western blotting for the cleaved forms of caspases and PARP after HOXA5 knockdown in TAMR cells. β-Actin was used as an internal control. All experiments 
were performed in triplicate. 





Figure 4. HOXA5 mediates invasion and migration abilities and stemness of breast cancer cells and induces aggressive phenotypes. (A) Matrigel invasion 
assay in parent MCF7, TAMR, and TAMR cells transfected with control or HOXA5 siRNAs. Representative images acquired by fluorescent microscopy after DAPI staining are 
shown. Quantitative interpretation was attained using ImageJ. (B) Migration assay in parent MCF7, TAMR, and TAMR cells transfected with control or HOXA5 siRNAs. 
Representative images acquired by fluorescent microscopy after DAPI staining are shown. Quantitative interpretation was attained using ImageJ. (C) Western blotting for 
epithelial and mesenchymal markers in parent MCF7, TAMR, and TAMR cells transfected with control or HOXA5 siRNAs. (D) Left panel shows representative microscopic 
images of breast cancer stem cell (BCSC) sphere growth of parent MCF, TAMR, and TAMR cells transfected with control or HOXA5 siRNAs. Right panel shows graphic 
presentation of the average sphere diameter. The data were retrieved and analyzed on the 14th day of spheroid culture. (E) Reverse transcription-quantitative PCR analysis of 
SOX2, OCT4, and NANOG in parent MCF7, TAMR, and TAMR cells transfected with control or HOXA5 siRNAs. All experiments were performed in triplicate. *** p < 0.001 
compared with MCF7 and siCON respectively by Student’s t-test or one-way ANOVA. 
 
HOXA5 mediates metastatic abilities and 
stemness of breast cancer cells resulting in 
aggressive phenotypes 
Next, the functional role of HOXA5 resulting in 
aggressive phenotypes in breast cancer cells 
associated with tamoxifen resistance was assessed. 
MCF7 cells have been reported to display poor 
invasiveness, whereas TAMR cells have enhanced 
invasive and migratory characteristics [41]. Therefore, 
we initially examined the invasion and migration 
abilities of the parent MCF7 and TAMR cells, as well 
as TAMR cells that have undergone siRNA-mediated 
HOXA5 knockdown. As expected, parent TAMR cells 
had considerably higher invading and migrating cell 
populations than parent MCF7 cells (Fig. 4A and 4B). 
Consequently, HOXA5-depleted TAMR cells 
displayed a dramatic diminishment in the invasive 
and migratory capacity compared to that of control 
cells (Fig. 4A and 4B). To better analyze this 
phenomenon, protein levels of molecular factors 
associated with invasion and migration, such as 
E-cadherin – an epithelial marker crucial for cell-cell 
adhesion, as well as N-cadherin and ZEB1 – key 
molecules involved in cell plasticity and promotion of 
EMT and metastasis, were explored through western 
blotting. The level of E-cadherin was markedly 
increased in parent MCF7 cells, whereas levels of 
N-cadherin and ZEB1 were noticeably increased in 
parent TAMR cells (Fig. 4C). Moreover, the 
knockdown of HOXA5 in TAMR cells promoted a 
reversal of EMT by upregulating the expression of the 
epithelial marker, E-cadherin, and downregulating 
the levels of the mesenchymal markers N-cadherin 
and ZEB1 (Fig. 4C). 
Increasing evidence is suggesting that a 
subpopulation of breast cancer stem cells contributes 
to the acquisition of drug resistance and ultimately 
metastasis and relapse in cancer patients. Hence, we 
evaluated whether TAMR cells display more 
stem-like properties when compared to MCF7 cells. 
We used the spheroid formation assay to analyze this 
phenotype. The spheroid formation assay is a method 
that allows the measurement of self-renewal 
capability and the multipotent nature of the cancer 
stem cell subpopulations within a cancer cell line. In 
the current study, the assay revealed that the size of 
the spheroids generated by parent TAMR cells was 
qualitatively more than 2-folds larger than that of 
parent MCF7 cells (Fig. 4D). To confirm that the 




enhanced spheroid formation was due to the elevated 
expression of HOXA5 in TAMR cells, 
HOXA5-depleted TAMR cells were used again to 
assess the spheroid formation capabilities. A 
significant reduction of spheroids in HOXA5 
knockdown TAMR cells compared to control cells 
was observed, supporting the role of HOXA5 
involvement in cancer stemness (Fig. 4D). To 
determine whether this phenomenon is accompanied 
by certain underlying molecular changes, we screened 
the cells for differential gene expression of stem cell 
markers, SOX2, OCT4, and NANOG. All three genes 
were upregulated in TAMR cells, supporting the 
results of the spheroid formation assay. When TAMR 
cells were depleted of HOXA5, we observed a 
significant downregulation in the expression levels of 
SOX2, OCT4, and NANOG genes (Fig. 4E). 
In summary, our data confirmed that HOXA5 
plays an important role in the regulation and 
maintenance of aggressiveness in tamoxifen-resistant 
breast cancer cells by mediating invasion and 
migration abilities as well as stem-like characteristics. 
Discussion 
In this study, we demonstrated that HOXA5 is a 
key molecule in activating the PI3K/AKT signaling 
pathway in tamoxifen-resistant breast cancer cells. We 
showed that it performs this role by downregulating 
p53 and p21 expression levels, resulting in impaired 
apoptosis and ultimately leading to tamoxifen 
resistance. We also revealed that HOXA5 contributes 
to breast cancer aggressiveness by modulating the 
expression of proteins involved in EMT. Therefore, 
the HOXA5/AKT/p53 axis is essential for promoting 
tamoxifen resistance in breast cancer. 
To date, there have been contradictory 
observations on the role of HOXA5 in cancer. Some 
studies suggest that HOXA5 functions as an 
oncogene, whereas some suggest that it functions as a 
tumor suppressor [42-46]. In particular, few studies 
have reported that HOXA5 is downregulated in 
breast cancer and that it functions as a tumor 
suppressor. Consequently, these studies showed that 
the overexpression of HOXA5 could prevent tumor 
progression and transition cancerous cells to a 
normal-like state [47-49]. Nonetheless, the role of 
HOXA5 in the acquisition of tamoxifen resistance in 
cells has never been reported. In the current study, we 
suggest that targeting the overexpression of HOXA5 
alone in breast cancer cells may not be therapeutically 
beneficial to combat tumorigenesis. In our analysis, 
we show evidence that high expression levels of 
HOXA5 is associated with an overall poor survival in 
ER+ breast cancer patients who have received 
tamoxifen treatment (Fig. 1C). Therefore, based on all 
our observations, we propose that overexpression of 
HOXA5 in breast cancer may not cause the cancer cell 
to revert back to a normal-like state. We have also 
shown that the elevated expression of HOXA5 in ER+ 
breast cancer could result in the acquisition of 
tamoxifen resistance. To corroborate the clinical 
relevance of the elevated expression of HOXA5 in 
conferring tamoxifen resistance, we used patient data 
retrieved from a publicly available gene expression 
profiling dataset (GSE1379) on 60 paired primary ER+ 
breast cancer patients and patients with recurrent 
cancer following tamoxifen monotherapy for 5 years. 
In agreement with the in vitro results, HOXA5 
expression was significantly higher in recurrent 
tumors, further supporting our hypothesis that 
HOXA5 is a potential biomarker of tamoxifen 
resistance (Fig. S3). However, additional investigation 
is essential to identify in detail the precise cellular and 
physiological functions of HOXA5 in the development 
of tamoxifen resistance. 
The p53 pathway is well known to be involved in 
apoptosis, and its relationship with HOXA5 
expression has also been reported. A previous study 
showed that HOXA5 functions as a direct 
transcriptional regulator of p53 by binding to its 
promoter region and also that expression levels of 
these two genes are positively correlated in ER+ 
breast cancer cells [49]. In this study, however, 
HOXA5 and p53 expressions were negatively 
correlated. This apparent and contradictory 
observation could be explained by the fact that p53 in 
our tamoxifen-resistant breast cancer model system is 
regulated by the PI3K/AKT signaling pathway, and 
not directly by HOXA5 itself. This phenomenon has 
also been demonstrated in mice, where Hoxa5 did not 
alter p53 expression [50]. Therefore, our results might 
have important implications in demonstrating that 
along with the expression of HOXA5, the PI3K/AKT 
signaling pathway needs to be simultaneously 
targeted to achieve efficient apoptotic effects 
mediated by p53. 
The elevated expression of HOXA5 also induced 
aggressive and stem cell-like properties in TAMR 
cells. Currently, a growing body of evidence suggests 
that tamoxifen-resistant breast cancers are more 
invasive, metastatic, and possess the ability to 
self-renew and generate diversely differentiated 
populations in a tumor [51, 52]. As a result, it is 
essential to study factors related to breast cancer stem 
cells (BCSCs) and their development. We 
demonstrated for the first time that HOXA5 
expression is necessary for the activation of the stem 
cell markers (SOX2, OCT4, and NANOG) and the 
enhanced formation of spheroids enriched with 
BCSCs. Further examination of the mechanism and 




factors leading to BCSC conversion during endocrine 
resistance development seems crucial for HOXA5 to 
be applied as a therapeutic target or biomarker in 
patients. 
Our study is the first to provide evidence that 
HOXA5 is not only involved in tumorigenesis and/or 
cancer progression but is also a molecular marker for 
tamoxifen resistance. In this study, HOXA5 
overexpression activated the PI3K/AKT signaling 
cascade, which in turn inhibited p53 and p21 
expression, resulting in reduced apoptosis in TAMR 
cells. In addition, HOXA5 induced migratory and 
invasive characteristics in TAMR cells by modulating 
the expression of epithelial and mesenchymal 
molecular markers. Elevated HOXA5 levels also 
promoted the formation of spheroids composed of 
BCSCs by upregulating the expression of stem cell 
markers (Fig. 5). Collectively, this study suggests that 
the HOXA5/AKT/p53 axis plays a crucial role in 
developing tamoxifen resistance and its associated 
phenotypes in ER+ breast cancer, and hence, could be 
considered as a potential therapeutic target for 
reversing tamoxifen resistance in breast cancer cells. 
 
 
Figure 5. A schematic model showing the potential role of HOXA5 in the tumorigenesis of breast cancer. In MCF7 breast cancer cells, the PRC2 complex leads 
to repressive histone modifications such as H3K27me3 at the putative promoter of HOXA5, resulting in gene expression inhibition. This leads to apoptosis (p53 and p21 
expression), epithelial phenotype (E-cadherin expression), and reduced breast cancer stem cell formation (decreased stemness marker expression). On the contrary, in TAMR 
cells, histone demethylases remove H3K27me3 marks at the HOXA5 putative promoter region. This leads to diminished apoptosis (inhibition of p53 and p21 expression), 
mesenchymal phenotype (N-cadherin and ZEB1 expression), and enhanced breast cancer stem cell formation (increased stemness marker expression). 





HOX: homeobox; PI3K: phosphoinositide 
3-kinase; AKT: protein kinase B; ER: estrogen 
receptor; PR: progesterone receptor; HER2: human 
epidermal growth factor receptor 2; SERMs: selective 
ER modulators; EMT: epithelial-mesenchymal 
transition; TAMR: tamoxifen-resistant; SOX2: sex 
determining region Y-box 2; OCT4: octamer-binding 
transcription factor 4; NANOG: nanog homeobox; 
BCSCs: breast cancer stem cells; ZEB1: zinc finger 
E-box binding homeobox 1; OS: overall survival. 
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